Physician profile
Subir Guha
NPI 1104871029
$12,660.51
in general payments reported to CMS, 2019-2025
65 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $3,088 · 2021: $1,878 · 2022: $1,460 · 2023: $1,590 · 2024: $1,445 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.73 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,844.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $1,396.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $765.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $690.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $574.53 | 2019-2025 | |
| Abbvie INC. | $556.34 | 2020-2025 | |
| Amgen INC. | $411.91 | 2020-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $367.03 | 2019-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $344.40 | 2019-2023 | Austedo Xr |
| Astellas Pharma US INC | $328.78 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $324.57 | 2019-2022 | |
| Beta Bionics, INC. | $290.57 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Biohaven Pharmaceutical Holding Company LTD. | $274.85 | 2022 | |
| Abbott Laboratories | $274.00 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.38 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subir Guha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.